Leucodelphinidin

Other Names

(2R,3S)-gallocatechin-4β-ol(2R,3S,4S)-2-(3,4,5-Trihydroxyphenyl)-3,4,5,7-chromanetetrol(2R,3S,4S)-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromene-3,4,5,7-tetrol(2R,3S,4S)-2-(3,4,5-trihydroxyphenyl)chroman-3,4,5,7-tetrol(2R,3S,4S)-3,3′,4,4′,5,5′,7-heptahydroxyflavan(2R,3S,4S)-3,4,5,7,3′,4′,5′-heptahydroxyflavan(2R,3S,4S)-3,4-Dihydro-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3,4,5,7-tetrol(2R,3S,4S)-leucodelfinidin(2R,3S,4S)-Leucodelphinidin(2R,3S,4S)-leucoefdin2-(3,4,5-Trihydroxyphenyl)-3,4,5,7-tetrahydroxychroman2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,4,5,7-tetrol2H-1-Benzopyran-3,4,5,7-tetrol, 3,4-dihydro-2-(3,4,5-trihydroxyphenyl)-, (2R,3S,4S)-3,3′,4,4′,5,5′,7-FlavanheptolLeucodelfinidinaLeucodelphidinLeukodelfinidinLeukodelphinidin

Synopsis

Leucodelphinidin: A Comprehensive Reference Article

1. Identity and Chemical Characterization

1.1 Names and Synonyms

Leucodelphinidin has the molecular formula C₁₅H₁₄O₈ and a molecular weight of 322.269. Its IUPAC systematic name is (2R,3S,4S)-2-(3,4,5-Trihydroxyphenyl)-3,4,5,7-chromanetetrol, and it carries several synonyms in the scientific literature, including (2R,3S)-gallocatechin-4β-ol, 3,3′,4,4′,5,5′,7-flavanheptol, leucoefdin, and leucoephdine. It is also recorded under the CAS registry number 98919-67-6 and carries the UNII code 7Y16CK877U.

1.2 Structural Classification

Leucodelphinidin is a colorless chemical compound related to leucoanthocyanidins. Leucoanthocyanidins are a class of colorless flavonoid compounds, specifically flavan-3,4-diols, that function as key intermediates in the plant flavonoid biosynthetic pathway, serving as precursors to both anthocyanins and proanthocyanidins (condensed tannins). These molecules possess a C6–C3–C6 carbon skeleton typical of flavonoids, with hydroxyl groups at the 3 and 4 positions of the C ring, enabling their conversion to colored anthocyanidins under acidic conditions or enzymatic catalysis.

Common variants within the leucoanthocyanidin class include leucocyanidin, leucodelphinidin, and leucopelargonidin, distinguished by the hydroxylation pattern on the B ring, which corresponds to their anthocyanidin derivatives cyanidin, delphinidin, and pelargonidin, respectively. Leucodelphinidin is specifically distinguished by a trihydroxylated B ring (with hydroxyl groups at the 3′, 4′, and 5′ positions), making it the most highly hydroxylated of the common leucoanthocyanidins and structurally equivalent to a flavan-3,4-diol form of gallocatechin. It is characterized as a 5:7:3′:4′:5′-pentahydroxyflavan-3:4-diol.

Leucoanthocyanidins exhibit stereoisomerism at the C2, C3, and C4 positions, with the natural cis form typically having (2R,3S,4S) configuration and the trans form (2R,3S,4R), influencing their substrate specificity in enzymatic conversions and stability in plant tissues. Two optical isomers of leucodelphinidin occur in nature: the leucoanthocyanidin of Karada bark (Cleistanthus collinus) has been identified as a (−)-leucodelphinidin, while a dextro-rotatory leucodelphinidin is found in the kino (gum) obtained from Eucalyptus pilularis, and it gives a different series of derivatives.

1.3 Physical Properties

As implied by its classification as a leucoanthocyanidin, leucodelphinidin is a colorless compound under ordinary conditions. From simple chemical concepts, delocalization of the positive charge over the A-ring is most effective for C-4 carbocations derived from flavan-3,4-diols with phloroglucinol-type A rings, providing a simple rationale for the striking instability of leucocyanidins, leucodelphinidins, and leucopelargonidins, and hence their relative absence from natural sources that contain oligomers derived from them. This chemical instability means leucodelphinidin is rarely encountered as a free, stable isolate in nature, and it is correspondingly challenging to work with analytically.

2. Natural Sources and Botanical Distribution

2.1 Primary Plant Sources

Leucodelphinidin can be found in Acacia auriculiformis, in the bark of Karada (Cleistanthus collinus), and in the kino (gum) from Eucalyptus pilularis.

Other species containing leucodelphinidin include Aesculus hippocastanum (Horse chestnut, in rind/bark/cortex), Arachis hypogaea (Earth nut, in seeds), Arbutus unedo (Arbutus, in the leaf), Caesalpinia pulcherrima (Barbados pride), Ceratonia siliqua (Carob, in the fruit), Hamamelis virginiana (American witch hazel, in the leaf), Hippophae rhamnoides (Sea buckthorn, in the leaf), Humulus lupulus (hops, in the leaf), Musa acuminata × balbisiana (Banana, in the fruit), Nelumbo nucifera (lotus, in the leaf), Phyllanthus emblica (Indian gooseberry/amla, in the rind/bark/cortex), and Quercus alba and Quercus robur (White and Common oak, in the rind/bark/cortex).

Additionally, some of the distinct compounds present in Ficus species plant parts include bengalenoside, leucodelphinidin, leucoanthocyanin, leucocyanidin, and their derivatives. The bark of Phyllanthus emblica contains proanthocyanidins, tannins, and leucodelphinidin.

Research into the biosynthesis of flavan-3-ols has demonstrated that leucodelphinidin also occurs transiently in tissue cultures of other species. Extracts of callus or cell suspension cultures from petioles of Ginkgo biloba catalyzed the production of (+)-gallocatechin from (+)-dihydromyricetin (5′-hydroxy-dihydroquercetin) along with the expected 3,4-cis-diol intermediate, leucodelphinidin, in a NADPH-dependent double-step reductase reaction at pH 7.4.

2.2 Phytochemical Context

Delphinidin and leucodelphinidin undergo enzymatic reduction to epigallocatechin and gallocatechin, respectively. Following reduction, both epigallocatechin and gallocatechin (or catechin, formed from leucocyanidin) undergo polymerization to form prodelphinidin. This positions leucodelphinidin at a critical metabolic branch point. The most common proanthocyanidins in food are procyanidins with a 3′,4′-dihydroxy substitution on the B ring and prodelphinidins with a 3′,4′,5′-trihydroxy substitution.

3. Biosynthesis and Biochemical Role

3.1 Enzymatic Formation via Dihydroflavonol 4-Reductase

Dihydroflavonol 4-reductase (DFR) is a key enzyme in the anthocyanin biosynthesis pathway, catalyzing the reduction of dihydroflavonols into leucoanthocyanidins. DFR (EC 1.1.1.219) uses dihydroquercetin (DHQ), dihydrokaempferol (DHK), and dihydromyricetin (DHM) as substrates to convert them into leucocyanidin, leucopelargonidin, and leucodelphinidin, respectively.

Dihydroflavonol 4-reductase uses dihydromyricetin (ampelopsin), NADPH, and 2H+ to produce leucodelphinidin and NADP+. This reaction is therefore NADPH-dependent and stereospecific.

DFR is a well-known enzyme of the flavonoid biosynthetic pathway mainly attributable to the biosynthesis and accumulation of anthocyanin and proanthocyanidin. Mostly, the enzyme contains a conserved NADP(H) binding domain, and a substrate binding domain that includes a 26 amino acid region; structural distinctions in this domain influence the preference of DFRs for dihydroflavonol substrates, thereby impacting the biosynthesis of anthocyanin metabolites.

3.2 Role in the Flavonoid Pathway

The upstream phenylpropanoid pathway converts the substrate L-phenylalanine to 4-coumarate CoA using phenylalanine ammonia-lyase (PAL), cinnamate 4-hydroxylase (C4H), and 4-coumarate CoA ligase (4CL). Next, 4-coumarate CoA is catalyzed by chalcone synthase (CHS), chalcone isomerase (CHI), and flavanone 3-hydroxylase (F3H) to form dihydroflavonol. Finally, dihydroflavonol 4-reductase (DFR) catalyzes dihydroflavanones to leucoanthocyanidins, which are then converted to anthocyanidin by anthocyanidindin synthase (ANS). Therefore, DFR is a key enzyme in anthocyanin biosynthesis that controls the carbon flux direction.

Leucoanthocyanidins that result from DFR can be converted to proanthocyanidin by leucoanthocyanidin reductase (LAR), while anthocyanidins resulting from LDOX can also be converted to another kind of proanthocyanidin by anthocyanidin reductase (ANR).

Leucodelphinidin is also an accepted substrate for leucoanthocyanidin reductase (LAR). Leucoanthocyanidin reductase removes the 4-hydroxyl from leucoanthocyanidins to produce the corresponding catechin. The preferred substrate is 3,4-cis-leucocyanidin, although 3,4-cis-leucodelphinidin and 3,4-cis-leucopelargonidin are also accepted.

In vitro chemical condensation of either catechin or epicatechin with leucocyanidin derived from dihydroquercetin gave fundamental support to the hypothesis that quinone methides or carbocations of leucoanthocyanidin derivatives are precursors of the extension units of proanthocyanidins, but this biogenetic sequence does not explain why the predominant extension units in proanthocyanidin oligomers or polymers are in the 2R,3R-2,3-cis configuration, and leucocyanidin, leucopelargonidin, or leucodelphinidin have not been isolated from plant tissues producing proanthocyanidins.

4. Traditional and Historical Use

4.1 Ayurvedic and South Asian Traditions

Leucodelphinidin is not, in traditional medicine systems, recognized as an isolated compound but rather is present within whole-plant preparations that have long, documented histories of use. The most significant traditional context involves plants in which leucodelphinidin has subsequently been identified.

The banyan tree (Ficus bengalensis) is among the most important of these sources in Ayurveda. Ficus bengalensis Linn (Moraceae), commonly known as the Banyan tree or Bargad, possesses extensive medicinal properties and is used in Ayurveda for diarrhea, as a diuretic, as a hypoglycemic, and as an anti-inflammatory agent. The leaves of F. bengalensis are used for ulcer protection, leprosy, and fever, and in inflammations in Ayurvedic practice. The milky juice is considered aphrodisiac, tonic, vulnerary, and maturant, also useful in piles, diseases of the nose, and gonorrhea. In Yunani medicine, the aerial root is considered styptic, and used in syphilis, biliousness, dysentery, and inflammation of the liver.

Phyllanthus emblica (amla or Indian gooseberry), another source of leucodelphinidin in its bark, has a long history of use in India and is called "amla" or "Indian gooseberry." As a tonic in Indian Ayurveda, it is often used for liver diseases. This fruit is known as "yuganzi" in China. It has a sweet and slightly astringent taste and is used for clearing heat from the throat and moistening the lung to arrest cough in Traditional Chinese Medicine (TCM). In Tibetan medicine this herb is used to treat blood and bile disease, and its preparations are clinically applicable to hypertension and anuria. In Thailand, it is named "makham pom" and is employed to treat gastrointestinal chronic diseases.

P. emblica is commonly used together with Terminalia chebula and T. belerica as the preparation known as "Triphala," which is used as a clinical treatment protocol for gastropathy in India and as a remedy for pestilence and fatigue in China.

Amla barks are rich in tannin and leucodelphinidin, which are known to enhance vascular function and provide cardiovascular protection.

4.2 Australian Aboriginal and Early European Settler Traditions

Eucalyptus kino, in which leucodelphinidin was first formally identified and characterized, has its own traditional context. In view of the ongoing interest in traditional medicines as a source of new therapeutic agents, a review of the natural formation, chemistry, and pharmacology as well as the technical and potential medical applications of kinos has been warranted, with particular reference to those of Australian Eucalyptus species and Aboriginal ethnomedical and also early European settlers' practices.

4.3 Traditional Uses of Other Leucodelphinidin-Bearing Plants

Hamamelis virginiana (American witch hazel), in which leucodelphinidin has been identified in the leaf, has an extensive traditional use in North American Indigenous and later European-derived medicine as a topical astringent and anti-inflammatory preparation, exploiting the condensed tannin-rich nature of the leaves and bark. Aesculus hippocastanum (Horse chestnut), which contains leucodelphinidin in its bark, has been widely used in European folk and herbal medicine for venous insufficiency. These uses, however, derive from the overall phytochemical content of these plants and are not attributable to leucodelphinidin specifically on the basis of current evidence.

5. Active Constituents and Mechanisms of Action

5.1 Structural Features Relevant to Biological Activity

Anthocyanidins, leucoanthocyanidins, and flavonols are natural compounds mainly known due to their reported biological activities, such as antiviral, antifungal, anti-inflammatory activities, and antioxidant activity. The high degree of hydroxylation in leucodelphinidin — with seven hydroxyl groups on the flavonoid scaffold — is considered to be central to its reactivity. The presence of three hydroxyl groups on the B ring (3′,4′,5′-trihydroxy substitution), in particular, is generally associated with enhanced radical-scavenging capacity within the flavonoid class.

5.2 Free Radical Scavenging and Antioxidant Activity

Anthocyanidins, leucoanthocyanidins, and flavonols exhibit antiviral, antifungal, anti-inflammatory, and antioxidant activity. Comparative structural, conformational, electronic, and nuclear magnetic resonance analysis has been applied to the reactivity of the chemical structures of primary anthocyanidins, leucoanthocyanidins, and flavonoids. The multiple phenolic hydroxyl groups of leucodelphinidin are the accepted basis for its electron-donating capacity and hydrogen-atom-transfer activity toward reactive oxygen and nitrogen species, which is the canonical mechanism of flavonoid antioxidant action.

5.3 Relationship with Delphinidin and Proanthocyanidins

Leucodelphinidin occupies an important position in the biosynthetic pathway leading to delphinidin, one of the most bioactive anthocyanidins. UFGT and reductase enzymes compete to form anthocyanins and proanthocyanidins, respectively. Delphinidin and leucodelphinidin undergo enzymatic reduction to epigallocatechin and gallocatechin, respectively. This means leucodelphinidin is biochemically connected both to the colored, bioactive anthocyanidin delphinidin and to the flavan-3-ols (epigallocatechin, gallocatechin), and the biological activities attributed to proanthocyanidins containing these units may partly reflect the activity of leucodelphinidin precursors.

6. Scientific Evidence by Area of Use

6.1 Hypoglycemic / Antidiabetic Activity

The most directly attributed pharmacological effect of leucodelphinidin in the peer-reviewed literature relates to blood glucose lowering. A leucodelphinidin derivative isolated from the bark of Ficus bengalensis Linn demonstrated hypoglycemic action at a dosage of 250 mg/kg given both in normal and alloxan-induced diabetic rats. Its action is closely similar to that of an effective dose of glibenclamide (2 mg/kg) tested under the same conditions. However, after a glucose load the plant product is only just significantly active but not as effective as the sulphonylurea.

A flavonoid of leucodelphinidin derivative isolated from F. bengalensis by Geetha et al. showed hypoglycemic activity in normal and alloxan-induced diabetic rats, comparable with the activity of glibenclamide.

Evidence strength assessment: This evidence is limited to animal models (rats). No human clinical trials investigating leucodelphinidin or a leucodelphinidin derivative specifically as a hypoglycemic agent have been identified in the peer-reviewed literature. The studies were conducted using an isolated derivative from Ficus bengalensis bark administered at 250 mg/kg in rodents; these results cannot be directly extrapolated to human dosing or efficacy.

6.2 Antiviral Activity: SARS-CoV-2 and Related Proteases

Studies have demonstrated that leucodelphinidin exhibits antiviral activity against SARS-CoV-2. This compound has a high affinity against the M^pro and PL^pro proteases from SARS-CoV-2, which induces conformational changes that impair their enzymatic activity.

The molecular mechanisms of action of bioflavonoids including leukodelphinidin and others — such as their anti-inflammatory, antioxidant, antiviral, bactericidal, angioprotective, and regenerative effects — have been subjects of systematic analysis of more than 150,000 biomedical references.

Evidence strength assessment: Available evidence for leucodelphinidin's antiviral activity against SARS-CoV-2 consists of computational (in silico) molecular docking and simulation studies. These are not clinical trials and not even cell-based antiviral assays. Docking studies identify binding affinity to target proteins but do not confirm antiviral efficacy in living systems. No human or animal in vivo data specifically on leucodelphinidin's antiviral effects have been identified. This evidence must be characterized as preliminary and computational only.

6.3 Antimicrobial Activity

Ficus benghalensis and Ficus religiosa studies have confirmed antimicrobial, antidiabetic, anti-inflammatory, and anticancer activity, providing a scientific basis for the use of the species in traditional medicines. Some of the distinct compounds present in Ficus species plant parts include bengalenoside, leucodelphinidin, leucoanthocyanin, leucocyanidin, and their derivatives. Leucodelphinidin is present within the extract matrix to which antimicrobial activity has been attributed, though the activity has not been isolated specifically to leucodelphinidin in controlled studies.

Evidence strength assessment: There are no peer-reviewed human clinical trials or controlled in vitro studies isolating leucodelphinidin specifically as an antimicrobial agent. Activity attributed to Ficus and other source plant extracts may be due to the complex mixture of phytochemicals present. Evidence is at most preliminary and associative.

6.4 Anti-inflammatory Activity

Leucodelphinidin, as a leucoanthocyanidin with close structural and biosynthetic relationships to potent flavonoid anti-inflammatories (such as epigallocatechin and gallocatechin), is hypothesized to possess anti-inflammatory activity. Leucoanthocyanidins as a class are mainly known due to their reported biological activities, including anti-inflammatory activity. However, specific mechanistic studies or controlled cell-based assays isolating leucodelphinidin's own anti-inflammatory effects are not documented in the literature surveyed, beyond the computational and class-based attributions.

Evidence strength assessment: No direct, leucodelphinidin-specific anti-inflammatory clinical or controlled in vitro trials have been identified. Activity is attributed primarily by chemical class analogy. This area requires primary experimental research specific to the compound.

6.5 Anticancer/Antiproliferative Activity

Studies reviewed on Ficus benghalensis and Ficus religiosa confirmed the antimicrobial, antidiabetic, anti-inflammatory, and anticancer activity, providing a scientific basis for the use of the species in traditional medicines. Leucodelphinidin is among the constituents identified in these species. However, no study directly isolating leucodelphinidin as the responsible anticancer agent in controlled human cell line, animal, or clinical studies has been identified.

Evidence strength assessment: Anticancer evidence is at the level of broad plant extract studies and chemical class reasoning. No clinical or controlled preclinical trials specific to leucodelphinidin's antiproliferative activity have been identified.

6.6 Cardiovascular and Vascular Effects

Amla barks are rich in tannin and leucodelphinidin, which are known to enhance vascular function and provide cardiovascular protection. Amla flowers contain geraniol and nerol, which modulate nervous system activity. This attribution, however, is based on the phytochemical composition of the bark matrix and has not been confirmed by studies isolating leucodelphinidin's specific vascular effects.

Evidence strength assessment: Evidence for cardiovascular benefits is associative and based on the identification of leucodelphinidin as a component in plant extracts with relevant traditional uses. No dedicated cardiovascular clinical or animal studies of leucodelphinidin as an isolated compound have been identified.

7. Related Plant Contexts and Associated Pharmacological Profiles

7.1 Phyllanthus emblica (Amla/Indian Gooseberry)

The fruit, leaves, and bark of Phyllanthus emblica are notably high in tannins, with the bark furthermore having leucodelphinidin. P. emblica Linn was firstly recorded in "Tang-Materia-Medica," and was included in the 2020 edition of the Chinese Pharmacopoeia with properties of sweet taste, cool nature, and belonging to lungs and stomach meridians. It is not only used as an edible fruit with rich phytonutrients, but also served as an ethnomedicine with the effects of clearing heat, cooling blood, digesting food, strengthening stomach, promoting fluid production, and relieving cough. In clinical practice, P. emblica Linn has been used to treat many diseases, including fever, asthma, cough, bronchitis, anemia, diabetes, cephalalgia, hematogenesis, ophthalmopathy, colic, flatulence, erysipelas, dysentery, leprosy, menorrhagia, inflammation, emaciation, hepatopathy, jaundice, hyperacidity, diarrhea, hemorrhages, leucorrhea, and dyspepsia.

7.2 Ficus bengalensis (Banyan Tree)

The Ficus species contain a range of flavonoids, phenolics, terpenes and terpenoids, fatty acids, sterols, organic acids, proteins, and long-chained hydrocarbon compounds. Some of the distinct compounds present in Ficus species plant parts include bengalenoside, leucodelphinidin, leucoanthocyanin, leucocyanidin, and derivatives. Leucodelphinidin is thus one component in a pharmacologically complex matrix that has yielded several distinct bioactive isolated compounds.

8. Dosage Forms and Reported Dosages

As of the literature surveyed, leucodelphinidin has not been developed as a standalone commercial dietary supplement, and no standardized dosage form exists. Dosage information in the scientific literature is limited to animal pharmacological studies:

A leucodelphinidin derivative isolated from the bark of Ficus bengalensis Linn demonstrated hypoglycemic action at a dosage of 250 mg/kg given both in normal and alloxan-induced diabetic rats. This dose was used in a rodent model only; no human equivalent dose has been established or validated.
No intravenous, topical, or standardized oral dosage forms of leucodelphinidin have been reported in clinical trials.
Leucodelphinidin-containing plant extracts (e.g., amla bark, Ficus bengalensis bark) appear in various Ayurvedic and traditional preparations, but the leucodelphinidin content of such preparations is not quantified in the available literature reviewed, and such preparations are not sold with leucodelphinidin as the labeled active ingredient.

9. Safety, Toxicity, and Interactions

9.1 Intrinsic Chemical Stability

From simple chemical concepts, delocalization of the positive charge over the A-ring is most effective for C-4 carbocations derived from flavan-3,4-diols with phloroglucinol-type A rings; this provides a simple rationale for the striking instability of leucocyanidins, leucodelphinidins, and leucopelargonidins, and hence their absence from natural sources containing oligomers derived from them. This inherent chemical instability is a primary consideration: leucodelphinidin is highly reactive and prone to spontaneous oxidation and polymerization under aqueous, acidic, and ambient oxygen conditions, which has significant implications for its formulation, shelf life, and pharmacokinetics if administered.

9.2 Absence of Dedicated Human Safety Data

No dedicated human safety, toxicity, or pharmacokinetic studies for leucodelphinidin as an isolated compound have been identified in the peer-reviewed literature. Because it exists primarily as a transient biosynthetic intermediate rather than a stable constituent of finished botanical products, and because it has not been developed as a commercial supplement ingredient, standard toxicological endpoints (LD₅₀, no-observed-adverse-effect level [NOAEL], maximum tolerated dose) have not been reported. All safety inferences must therefore draw on the broader class of flavonoid flavan-3,4-diols and the safety profiles of leucodelphinidin-containing plant preparations, for which independent safety considerations apply.

9.3 Instability and Conversion Products

Dihydroflavonol is catalyzed by chalcone synthase, chalcone isomerase, and flavanone 3-hydroxylase (F3H) to form dihydroflavonol, and then DFR catalyzes dihydroflavanones to leucoanthocyanidins, which are then converted to anthocyanidin by anthocyanidindin synthase (ANS). Upon acidification or heating, leucodelphinidin readily converts to its corresponding anthocyanidin, delphinidin, producing the characteristic red-purple coloration of anthocyanidins. Leucodelphinidin also undergoes enzymatic reduction to gallocatechin. In a biological system, ingested leucodelphinidin could therefore be converted to gallocatechin or delphinidin; the safety and pharmacology of these downstream metabolites are better characterized than leucodelphinidin itself.

9.4 Context of Plant-Source Safety

The botanical sources of leucodelphinidin in which the compound has been identified have broadly acceptable safety profiles in food-use quantities. Phyllanthus emblica (amla) fruit is widely consumed as a food and is an ingredient in numerous licensed Ayurvedic and TCM formulations. Ficus bengalensis bark preparations are used medicinally in traditional systems but are not standardized pharmaceutical products. Hamamelis virginiana (witch hazel) preparations are widely used topically and are recognized in Western pharmacopoeias. The presence of leucodelphinidin in these sources does not by itself establish safety or dosage of leucodelphinidin as an isolated constituent.

9.5 Potential for Drug-Like Interactions

No specific drug interaction studies on leucodelphinidin have been published. Given its structural similarities to catechins and other flavan-3-ols, and the documented effects of closely related polyphenols on drug-metabolizing enzymes (particularly CYP450 isoforms and P-glycoprotein), potential pharmacokinetic interactions cannot be excluded but remain uninvestigated for leucodelphinidin specifically.

10. Research Gaps and Current Status

Leucodelphinidin remains primarily an object of plant biochemistry and biosynthesis research rather than clinical pharmacology. Key gaps in the evidence base include:

Absence of any human clinical trials directly investigating leucodelphinidin as an isolated compound.
Absence of standardized animal pharmacokinetic and bioavailability data (absorption, distribution, metabolism, excretion) for leucodelphinidin itself, as distinct from its conversion products (gallocatechin, delphinidin).
Lack of dose-response data in any model for most claimed biological activities (antioxidant, antimicrobial, anti-inflammatory, anticancer).
The compound's chemical instability significantly complicates isolation, storage, analysis, and in vivo study.
Antiviral activity against SARS-CoV-2 proteases is currently supported only by computational molecular docking studies, with no cell-based or in vivo confirmation.
The hypoglycemic activity attributed to a leucodelphinidin derivative from Ficus bengalensis is the most experimentally grounded specific pharmacological claim, but is limited to rodent models at a dose of 250 mg/kg — a standard preclinical starting point, not a clinical translation.

References

Health Conditions

Health conditions that Leucodelphinidin may help support.

No conditions available.

Body Systems

Body systems that Leucodelphinidin may help support.

No body systems available.